Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition
The immunocytokine PD1-IL2v was designed to overcome liabilities and improve efficacy of IL-2 therapies. PD1-IL2v preferentially targets PD-1+ T-cells and acts on antigen-specific stem-like PD-1+ TCF-1+ CD8+ T-cells expanding and differentiating them towards better effectors resulting in superior ef...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2197360 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850238219310858240 |
|---|---|
| author | Laura Codarri Deak Masao Hashimoto Pablo Umaña Christian Klein |
| author_facet | Laura Codarri Deak Masao Hashimoto Pablo Umaña Christian Klein |
| author_sort | Laura Codarri Deak |
| collection | DOAJ |
| description | The immunocytokine PD1-IL2v was designed to overcome liabilities and improve efficacy of IL-2 therapies. PD1-IL2v preferentially targets PD-1+ T-cells and acts on antigen-specific stem-like PD-1+ TCF-1+ CD8+ T-cells expanding and differentiating them towards better effectors resulting in superior efficacy in LCMV chronic infection and tumor models compared to checkpoint inhibition. |
| format | Article |
| id | doaj-art-309d650fc20346a19de0ef750266fa1d |
| institution | OA Journals |
| issn | 2162-402X |
| language | English |
| publishDate | 2023-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj-art-309d650fc20346a19de0ef750266fa1d2025-08-20T02:01:30ZengTaylor & Francis GroupOncoImmunology2162-402X2023-12-0112110.1080/2162402X.2023.2197360Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibitionLaura Codarri Deak0Masao Hashimoto1Pablo Umaña2Christian Klein3Roche Innovation Center Zurich, Cancer Immunotherapy Discovery, Roche Pharma Research and Early Development, Schlieren, SwitzerlandEmory Vaccine Center and Department of Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, USARoche Innovation Center Zurich, Cancer Immunotherapy Discovery, Roche Pharma Research and Early Development, Schlieren, SwitzerlandRoche Innovation Center Zurich, Cancer Immunotherapy Discovery, Roche Pharma Research and Early Development, Schlieren, SwitzerlandThe immunocytokine PD1-IL2v was designed to overcome liabilities and improve efficacy of IL-2 therapies. PD1-IL2v preferentially targets PD-1+ T-cells and acts on antigen-specific stem-like PD-1+ TCF-1+ CD8+ T-cells expanding and differentiating them towards better effectors resulting in superior efficacy in LCMV chronic infection and tumor models compared to checkpoint inhibition.https://www.tandfonline.com/doi/10.1080/2162402X.2023.2197360Eciskafusp alfaIL-2PD-1PD1-IL2vRG6279TCF-1 |
| spellingShingle | Laura Codarri Deak Masao Hashimoto Pablo Umaña Christian Klein Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition OncoImmunology Eciskafusp alfa IL-2 PD-1 PD1-IL2v RG6279 TCF-1 |
| title | Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition |
| title_full | Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition |
| title_fullStr | Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition |
| title_full_unstemmed | Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition |
| title_short | Beyond checkpoint inhibition: PD-1 cis-targeting of an IL-2Rβγ-biased interleukin-2 variant as a novel approach to build on checkpoint inhibition |
| title_sort | beyond checkpoint inhibition pd 1 cis targeting of an il 2rβγ biased interleukin 2 variant as a novel approach to build on checkpoint inhibition |
| topic | Eciskafusp alfa IL-2 PD-1 PD1-IL2v RG6279 TCF-1 |
| url | https://www.tandfonline.com/doi/10.1080/2162402X.2023.2197360 |
| work_keys_str_mv | AT lauracodarrideak beyondcheckpointinhibitionpd1cistargetingofanil2rbgbiasedinterleukin2variantasanovelapproachtobuildoncheckpointinhibition AT masaohashimoto beyondcheckpointinhibitionpd1cistargetingofanil2rbgbiasedinterleukin2variantasanovelapproachtobuildoncheckpointinhibition AT pabloumana beyondcheckpointinhibitionpd1cistargetingofanil2rbgbiasedinterleukin2variantasanovelapproachtobuildoncheckpointinhibition AT christianklein beyondcheckpointinhibitionpd1cistargetingofanil2rbgbiasedinterleukin2variantasanovelapproachtobuildoncheckpointinhibition |